Casebia Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:N/A
Industry:Biotech
Founded:2016
Lead Investor(s):N/A
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Casebia Therapeutics's estimated annual revenue is currently $16.9M per year.
  • Casebia Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Casebia Therapeutics has 109 Employees.
  • Casebia Therapeutics grew their employee count by 38% last year.
  • Casebia Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$8.7M5660%N/A
Tango Therapeut...
$12.9M8338%N/A
Compass Therape...
$16.4M10614%N/A
Cell Signaling ...
$89.4M577N/AN/A
Momenta Pharmac...
N/A220N/AN/A
Emulate
$15.3M99-17%N/A
ArQule
N/A94N/AN/A
Hamilton Storag...
$17.2M1119%N/A
Alnylam Pharmac...
$74.9M127731%N/A
Transgenomic
N/A47N/AN/A
Missing a competitor? Contribute!?
Submit

Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.

keywords:N/A

109

Number of Employees

$16.9M

Revenue (est)

1

Current Jobs

38%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Abraham ScariaVp, Head Of OphthalmologyEmail Available
Adel NadaChief Medical Officer
Ileen WinickSenior Vice President, Human Resources
Debi HarmonSenior Director Human Resources
Vilmary TorresAccounting Manager
Robin WalkerSenior Vice President, Head Of Legal
Bindu RanganathManager Fp&a
Joshua MerrittDirector, Manufacturing And Process Development (aav)
Christopher ChengDirector, RNA Technology
Andy ScharenbergChief Scientific Officer

Casebia Therapeutics News

09/03/2019 - Bayer nabs new dealmaker—but after Monsanto, is there ...

... with small startups, including its 2016 Casebia Therapeutics, formed by Bayer and CRISPR Therapeutics, which aims to cure blood disorders ...

08/12/2019 - Top 10 Companies Leveraging Gene Editing in 2019

Editas and Intellia, like CRISPR Therapeutics, reached 12-month lows .... Casebia was launched in December 2015 when Bayer agreed to pay ...

08/27/2019 - Gene editing companies oppose altering of embryos

Thirteen biopharma companies, including Sangamo Therapeutics and ... James Burns, CEO of Casebia Therapeutics, one of the co-signers, ...

Casebia Therapeutics Executive Hires

DateNameTitleReference
2016-11-02James BurnsPresident/Chief Executive OfficerArticle
2017-05-12Ellen RidgeSVP OperationsArticle
2017-05-12Abraham ScariaVP OphthalmologyArticle
2017-06-29Robin WalkerVP Head of LegalArticle
2017-09-11Michael LaskaVP CMC Development and ManufacturingArticle
2018-05-31Amy JenningsHead Its Regulatory AffairsArticle
2018-11-01Adel NadaChief Medical OfficerArticle